This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Earnings Preview: Cooper Cos. (COO) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PDCO vs. COO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PDCO vs. COO: Which Stock Is the Better Value Option?
3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis
by Sriparna Ghosal
Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.
New Strong Sell Stocks for July 2nd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
New Strong Sell Stocks for June 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Near-Term Outlook Bleak for Medical Dental Supplies Industry
by Trina Mukherjee
Digital influence coupled with AI & Robotics can drive the medical dental supplies industry amid the coronavirus-induced crisis.
Cooper Companies (COO) Misses on Q2 Earnings and Revenues
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter earnings reflect dismal segmental performance and decline in revenues.
Cooper Cos. (COO) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of -29.11% and -10.02%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter performance is likely to reflect better-than-expected performance at CVI and CSI.
Analysts Estimate Cooper Cos. (COO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to gain traction from its robustly performing CVI and CSI businesses.
Masimo SafetyNet to Help Clinicians Fight Coronavirus Better
by Zacks Equity Research
Masimo (MASI) announces the full market release of Masimo SafetyNet, which is a remote patient management solution that will help in the fight against the COVID-19 pandemic.
AngioDyanamics (ANGO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its ARIES SARS-CoV-2 Assay, which will be used to rapidly detect the virus causing COVID-19.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako, broad product portfolio and solid international growth. However, pricing pressure raises concern.
Here's Why You Should Hold on to Avanos Medical Stock Now
by Zacks Equity Research
Avanos Medical (AVNS) continues to benefit from strong performing segments and robust product portfolio. However, weak performance at Acute Pain unit raises concern.
BD Gets EUA for New Test to Combat the Coronavirus Crisis
by Zacks Equity Research
BD (BDX) partners with BioGX to introduce a new diagnostic test to help hospitals boost the capacity of quick, on-site testing of COVID-19.
Cooper Cos. (COO) Down 14% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cooper Cos. (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MCK vs. COO: Which Stock Is the Better Value Option?
by Zacks Equity Research
MCK vs. COO: Which Stock Is the Better Value Option?
Here's Why You Should Add Integer Holdings to Your Portfolio
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from solid presence in the broader MedTech space and portfolio management.
BD Launches New Test to Help Combat the Coronavirus Outbreak
by Zacks Equity Research
BD (BDX), along with BioMedomics, launches a new point-of-care test to help fight the coronavirus outbreak.
Allscripts Offers Telehealth Support Amid Coronavirus Outbreak
by Zacks Equity Research
Allscripts (MDRX) offers simplified telehealth implementation to health systems through FollowMyHealth to provide telehealth visit capabilities to their patients quickly.
Here's Why You Should Invest in McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to gain traction from its multi-year strategic growth initiative and distribution solutions segment.
Why You Should Invest in Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment, diversified product portfolio and strategic buyouts.
Luminex (LMNX) Receives EUA for Coronavirus Detection Test
by Zacks Equity Research
Luminex (LMNX) receives EUA for its NxTAG CoV Extended Panel that will be used to detect the SARS-CoV-2 virus.